Nov 17th, 2016 – Seattle Angel Conference X – Episode 10 of 12
Bob Crimmins, the emcee of the tenth Seattle Angel Conference, introduces Dema Poppa, the CEO of Invio, who explains how they make enterprise SaaS for clinical trials with a cloud-based platform for sharing medical research data in a regulatory compliant way between the participating hospitals and the central research administration.
Dema describes how Invio‘s business model is set up to scale with complexity studies and targets organizations that do research in parallel which creates potential up-sale opportunities. He introduces Invio‘s team members and explains how their combined expertise will contribute to their overall success.
Adam Glass, the SAC Due Diligence Lead, comments on how thoughtful Invio‘s customer focus was in respect to the long-term value they bring to filling a niche market. Adam asks how Invio is going to build their sales platform before they burn out. Dema explains how they is a discover-able market through regulatory compliance that provides several methods for keeping their pipeline full with prospective clients.
Invio is one of six Finalists that have endured a twelve week elimination process for an investment by the Seattle Angel group. Each Finalist has ten minutes to make their final presentation before an audience of angel investors which is followed up by a five minute Q & A session with their Due Diligence Lead.
After all the Finalists have made their presentation, the angel investors deliberate and vote on which business they will invest their time, money and energy into growing.
For more information visit: www.SeattleAngelConference.com.